丰原药业(000153) - 2015 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥397,367,769.64, a decrease of 5.13% year-on-year[8]. - Net profit attributable to shareholders decreased by 19.87% to ¥13,678,661.30[8]. - Net profit attributable to shareholders after deducting non-recurring gains and losses fell by 31.65% to ¥11,422,787.58[8]. - Basic earnings per share decreased by 19.93% to ¥0.0438[8]. - The weighted average return on net assets was 1.65%, a decrease of 0.09% compared to the previous year[8]. - There are no significant changes in net profit expected compared to the previous year[22]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,290,038,890.62, an increase of 2.35% compared to the previous year[8]. - Net assets attributable to shareholders increased by 2.99% to ¥1,145,683,440.75[8]. - Short-term loans increased by 31.75% to CNY 349.4 million due to an increase in bank borrowings[17]. - Accounts payable increased by 100% to CNY 6.82 million as a result of higher payments made via bank acceptance bills[17]. - Prepayments decreased by 39.82% to CNY 21.56 million due to a reduction in customer advance payments[17]. - Tax payable decreased by 95.56% to CNY 218,919.35 due to a reduction in corporate income tax[17]. - Non-current liabilities due within one year decreased by 44.72% to CNY 109.48 million as the company repaid maturing long-term loans[17]. Cash Flow - Cash flow from operating activities for the year-to-date increased significantly by 167.53% to ¥41,148,023.69[8]. - Cash generated from operating activities increased by 167.53% to CNY 41.15 million[17]. - Cash used in investing activities decreased by 68.67% to CNY -37.83 million, indicating reduced cash outflow for fixed assets[17]. - Cash used in financing activities decreased by 48.00% to CNY -17.94 million, reflecting lower cash payments related to financing activities[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,998[10]. - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of the shares, totaling 35,842,137 shares[10]. - The company has fulfilled all commitments made to minority shareholders in a timely manner[21]. Technology and Business Strategy - The company is planning a significant technology transfer related to recombinant interleukin-12 with the University of Science and Technology of China[18]. - The company signed a memorandum for the technology transfer of recombinant interleukin-12 on July 25, 2015[19]. - The company has signed a memorandum for the transfer of interleukin-12 technology with the University of Science and Technology of China[25]. - The company is committed to integrating pharmaceutical-related assets for overall listing to eliminate potential competition with its controlling shareholder[21]. - The company has made commitments to avoid any business competition with its controlling shareholder during its tenure[21]. Compliance and Investments - There are no securities investments reported during the reporting period[22]. - The company has not engaged in any derivative investments during the reporting period[24]. - There are no violations regarding external guarantees during the reporting period[26]. - The company has not experienced any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[27].